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Abstract
Acute gastroenteritis caused by noroviruses often has a duration of 2–3 days and is characteristically self-limiting. In contrast, chronic
infection caused by noroviruses in immunocompromised individuals can last from weeks to years, making clinical management difﬁcult. The
mechanisms by which noroviruses establish persistent infection, and the role of immunocompromised hosts as a reservoir for noroviruses
in the general human population, are not known. However, study of this patient cohort may lead to new insights into norovirus biology and
approaches to treatment.
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Noroviruses belong to the genus Norovirus, a large and
diverse genus in the positive-strand RNA virus family
Caliciviridae. The association of noroviruses with acute
gastroenteritis is well established. The disease burden in the
USA alone is an estimated 19–21 million episodes of gastro-
enteritis annually, with c. 400 000 emergency department
visits, 56 000–71 000 hospitalizations, and as many as 570–
800 deaths [1,2]. Noroviruses have been reported as the
leading cause of severe diarrhoea in infants and young
children requiring medical intervention in the USA, now that
rotavirus vaccines have been successfully deployed [3,4].
Vaccines for noroviruses are not yet available, but recombi-
nant virus-like particle vaccines have shown promise in clinical
trials [5].
Noroviruses can establish a persistent infection in immu-
nocompromised hosts, resulting in prolonged virus shedding
and gastrointestinal disease that, over time, can become
increasingly debilitating and life-threatening [6–8]. In a review
of 123 deaths attributed to noroviruses, a serious underlying
condition was reported for 17 individuals at the time of death,
with ten (58%) of the deaths occurring in patients who were
immunocompromised by chemotherapy or transplantation [9].
There is presently no virus-speciﬁc drug available to treat
norovirus infection, although the urgent need for such drugs in
immunocompromised patients has gained recent attention [8].
This review will focus on the current understanding of chronic
norovirus infection that characteristically occurs in immuno-
compromised individuals, and the prospects for prevention
and treatment.
Immunocompromised Patient Groups at
Risk
Children
In early studies of the genetic diversity of noroviruses, the
Toronto virus (formerly called ‘minireovirus’ and now classi-
ﬁed as a reference GII.3 norovirus strain) was identiﬁed as a
genetically distinct ‘Norwalk-like virus’ in sick children receiv-
ing care at the Children’s Hospital in Toronto, Canada [10].
Four of the 11 paediatric patients studied at the Chil-
dren’s Hospital shedding norovirus were designated as
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immunosuppressed, with underlying conditions of leukaemia,
post-liver transplant status, or severe combined immunodeﬁ-
ciency. Since then, an increasing number of case study
descriptions have linked norovirus infection to conditions in
children that are characteristically associated with immuno-
suppression, such as inherited immune disorders [11–13],
small-bowel transplantation [14], kidney transplantation [15],
haematopoietic stem cell transplantation (HSCT) [16,17], and
cancer or cancer treatment [17–19]. Noroviruses have also
been detected in children experiencing complications that may
arise from immunosuppression. Haemophagocytic lymphoh-
istiocytosis was reported recently in association with chronic
norovirus infection of duration 40 days following bone mar-
row transplantation for treatment of relapsed myelogenous
leukaemia in a 24-month-old child [20]. In a study of 27
paediatric patients with pneumatosis intestinalis, 17 (63%)
were immunocompromised, with noroviruses being the pre-
dominant pathogens detected (23.5% prevalence) following
screening for bacterial and viral agents [21]. The ﬁrst study to
systematically examine the prevalence of noroviruses in
children with inherited immune deﬁciencies reported that
noroviruses were the most commonly detected pathogens in
the 62 children studied, and that shedding was prolonged, with
57.1% of faecal samples still being positive after a median of
9.5 months of follow-up [13]. It is of interest that the
investigators reported evidence of norovirus viraemia in 25%
of these paediatric cases. A retrospective study of diarrhoea in
55 haematopoietic stem cell transplant recipients aged
<21 years showed that 49 developed diarrhoea and eight
(6.3%) were positive for the presence of norovirus in stool
[22]. The overall cumulative incidence of norovirus infection in
this cohort was 12.9%, and the median time for norovirus
clearance was 145 days (range: 13–263 days). A survey of two
paediatric hospitals in the metropolitan Atlanta area that
examined the prevalence of noroviruses [23] reported the
detection of noroviruses in 15 of 92 (16.3%) of the patient
stools tested. It was noteworthy that 11 of 15 (73.3%) of the
norovirus-positive stools were obtained from immunocom-
promised patients (n = 47), indicating an overall norovirus
prevalence of 23.4% in this group.
Adults
Chronic norovirus infection has been documented in adults
following HSCT [24–27], kidney transplantation [28–31], heart
transplantation [32], human immunodeﬁciency virus infection
[33], and cancer or cancer treatment [18,34]. Elderly popu-
lations are at increased risk for a serious outcome from
infectious diseases [35], including norovirus illness [36–38],
with declining immune function thought to be a contributory
factor.
Nosocomial Norovirus Infections
Risk factors in nosocomial outbreaks
Noroviruses constitute the leading cause of severe viral
gastroenteritis prompting admission to a hospital emergency
department [39]. A number of studies have also documented
the important role of noroviruses in nosocomial infections. In
a survey of 289 hospitals in the USA that had initiated outbreak
investigations in the previous 12 months, noroviruses were
the most frequently detected nosocomial pathogens, account-
ing for 53 of 291 (18.2%) of the investigated conﬁrmed
outbreaks and resulting in the highest rate of hospital unit
closures (65%) [40]. An analysis of risk factors for norovirus
disease in one university hospital found that immunocompro-
mised patients were at increased risk for a severe clinical
outcome following norovirus infection [38]. Prolonged shed-
ding by immunocompromised individuals has been suggested as
a source of virus strains for nosocomial infections [41]. A
nosocomial outbreak of norovirus in a bone marrow trans-
plant unit was attributed, in part, to the longer shedding
periods and hospital stays of these patients [26]. An immuno-
compromised patient suffering from an acute norovirus
infection was identiﬁed as an index case for the introduction
of norovirus into a hospital transplantation care unit where the
patient was admitted for treatment of complications resulting
from graft-versus-host disease following HSCT [27].
Genetic diversity and evolution of noroviruses in nosocomial
outbreaks
Persistent or chronic viral infections are known to be caused
by many positive-strand RNA viruses, and they are well
documented in members of the family Caliciviridae. Feline
calicivirus (FCV), a member of the genus Vesivirus and an agent
of upper respiratory illness in cats, can establish a chronic
infection in cats, even in the presence of prior vaccination and
an intact immune system [42]. The upper respiratory tract was
proposed as a major site of FCV persistence [43]. Moreover,
evidence was shown for the evolution of antigenic variation in
FCV strains over time, suggesting the presence of selective
pressure driven by an adaptive immune response [44]. Murine
norovirus (MNV), which is more closely related to human
noroviruses, can establish asymptomatic and persistent infec-
tion in mice, with both virus and mouse host differences being
linked to chronic infection [45,46]. It has been proposed that
the colon may be an important site of persistent MNV
replication in mice [47,48], and it is of interest that lesions in
the colon have been proposed as sites of virus replication in
preterm babies with severe norovirus infection [49]. One
study identiﬁed the presence of MNV antigen in the mesen-
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teric lymph nodes of certain immunodeﬁcient mice, suggesting
lymphoid tissue as another site of persistent infection [50].
Possible adaptive changes during persistent MNV infection
have been linked to the N-terminal open reading frame 1
protein (NS1/2) [48], the RNA-dependent RNA polymerase
(NS7) [47], and the minor structural protein VP2 [47], but the
mechanisms of norovirus persistence will require additional
investigation.
Norovirus infection in immunocompromised patients can
begin with an episode of acute gastroenteritis, but the inability
to clear the virus can lead to chronic infection. There is
presently no evidence for naturally occurring norovirus strains
that have evolved to preferentially establish persistent infec-
tion in human hosts. The predominant norovirus genotypes
reported in immunocompromised individuals belong to geno-
group II, which is reﬂective of the predominance of this
genotype as the cause of acute gastroenteritis in the general
population. Table 1 summarizes representative studies, many
in hospitals or transplant units, reporting the genotypes of
strains associated with chronic infections in immunocompro-
mised hosts.
A growing number of outbreak investigations in hospitals
have employed molecular techniques to elucidate the source
and spread of noroviruses in nosocomial outbreaks [17,51–
53]. An investigation of three separate norovirus transmission
events resulting in gastroenteritis outbreaks in a hospital linked
the source to three immunocompromised individuals with
probable chronic shedding [41]. Sequence analysis of norovi-
ruses shed over time in chronically ill patients may allow an
in-depth understanding of virus adaptation and spread in the
presence of little or no host immune pressure [54,55]. There is
evidence that noroviruses in chronically infected immunocom-
promised patients accrue amino acid substitutions on the
outer surface of the viral capsid over time that may change
their antigenic proﬁle [32,55] (Fig. 1). An important area of
future investigation will be to determine whether these
mutations are meaningful for treatment and clinical manage-
ment.
The infectivity and transmissibility of noroviruses shed by
chronically infected individuals in comparison with those of
noroviruses shed by individuals with acute infection has not
been fully established. One model proposes that norovirus
transmission is most efﬁcient in the early phase of an acute
norovirus infection [56], when virus titres in stools have been
shown to be highest [57]. A detailed analysis of three
nosocomial outbreaks in different facilities found that norovi-
rus gastroenteritis cases were most often linked to transmis-
sion events involving symptomatic patients or healthcare
workers, with asymptomatic individuals being less likely to
transmit virus [58]. In healthy adult volunteers challenged with
Norwalk virus, the peak of virus shedding (median concentra-
tion reported as 95 9 109 genomic copies per gram of
faeces), occurred at a median of day 4 after inoculation,
whether infection was symptomatic or asymptomatic, and the
median duration of shedding was 28 days, well after symptoms
had resolved [59]. The prevalence of asymptomatic infection in
immunocompetent hosts has been estimated to be as high as
12% [60], indicating that it will be challenging to determine
whether chronic shedders serve as a reservoir for the general
population without intense epidemiological surveillance and
viral genome sequencing. Immunocompromised children with
norovirus infection were reported to shed median viral
concentrations of 3.6 9 108 cDNA copies per gram of stool
collected between 2 days and 14 days post-onset [19]. In
another study that examined norovirus viral loads in highly
immunosuppressed patients and children, the median viral load
was reported to be 2.9 9 107 genomic copies per milliliter of
stool [61]. Further study of viral load and evolution in
immunocompromised individuals will be needed to correlate
virus titre with symptoms, severity of disease, and efﬁciency of
transmission [62].
Treatment and Control of Norovirus
Infection in Immunocompromised Hosts
Treatment
There is currently no speciﬁc antiviral drug for the treatment
of norovirus gastroenteritis. Supportive ﬂuid replacement
therapy can be used to prevent dehydration, and nutritional
TABLE 1. Norovirus genotypes
detected in immunocompromised
patients
Setting (country) Underlying condition or treatment Genotypes Reference
Children’s hospital (Canada) Cancer, liver transplantation, SCIDs GII.3 [10]
Hospital (UK) Bone marrow transplantation GII.4 [52]
Hospital (UK) HSCT GII.3, GII.4, GII.7 [24]
Hospital (Switzerland) HSCT, lung transplantation GII.4 [25]
Hospital (The Netherlands) Cancer, leukopenia, HSCT GII.3, GII.4 [17]
Hospital (Germany) Cancer GII.3, GII.4 [19]
Individual patient (Sweden) Heart transplantation GII.3 [32]
Hospital (USA) Intestinal transplantation GII.4 [14]
HSCT, haematopoietic stem cell transplantation; SCID, severe combined immunodeﬁciency.
ª2014 The Author
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 717–723
CMI Green Noroviruses in the immunocompromised 719
supplementation may be required [6]. Nausea and diarrhoea,
which are hallmarks of norovirus disease, are common in
immunocompromised patients, making laboratory conﬁrma-
tion of norovirus infection an important diagnostic tool in
patient management. For example, diarrhoea occurred in 79%
of adult allogeneic stem cell transplant recipients in one study,
but the aetiology could not be linked to any known aetiological
infectious agent [63]. Conditioning therapy prior to transplan-
tation and complications following transplantation, such as
graft-versus-host disease, may cause diarrhoea [6,27]. A
number of treatment strategies have been reported to
improve chronic norovirus infection in immunocompromised
individuals, including adjustment of immunosuppressive ther-
apy (IST) drug types and dose levels [14,24,25,29,30], drugs
approved for other pathogens [34], and passive c-globulin
therapy [31,33,64]. The recovery of normal intestinal mor-
phology following reduction of IST in a norovirus-infected child
who had undergone a small-bowel transplant is shown in
Fig. 2. In mice, it was possible to clear persistent MNV
infection in immunocompromised animals [59] with neutraliz-
ing antibodies, showing the potential beneﬁt of passive
immunotherapy [65]. However, there are also reports of
treatment failure with breast milk, c-globulin and IST adjust-
ment in one immunocompromised patient [32].
Side view Top view
(a) (b)
FIG. 1. Modelling of amino acid changes on the surface of a GII.4 norovirus capsid following chronic infection over a period of almost 1 year in an
immunocompromised patient (adapted from reference [55]). (a) Side view of VP1 dimer. (b) Top view of VP1 dimer. Amino acids that differ over
time are indicated in dark grey, and histo-blood group antigen-binding sites are shown as stick models. It is noteworthy that the majority of mutations
are predicted to occur on the exposed surface of the viral capsid. A number of mutations correspond to antigenic changes as described in the cited
article.
Jejunal biopsy post-transplant 
day 296, positive for norovirus 
Jejunal biopsy post-transplant 
day 317, negative for norovirus 
after lowering of IST
(a) (b)
FIG. 2. Intestinal biopsy of a paediatric
small-intestine transplant patient. (a)
During acute norovirus infection at
day 296 post-transplant. (b) After
resolution of symptoms at day 317
post-transplant following reduction of
immunosuppressive therapy (IST), which
allowed virus clearance. Note the severe
blunting of intestinal villi during acute
infection, and the regeneration of normal
intestinal morphology after virus
clearance. Adapted from reference [14].
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Infection control
Noroviruses are highly infectious and stable in the environment.
A review of transmission routes in 54 nosocomial outbreaks
identiﬁed person-to-person spread (18.5%) and foodborne
sources (3.7%) as the major known routes, but a clear route of
transmission could not be identiﬁed in the majority (77.8%) of
the outbreaks [66]. Infection control has remained the ﬁrst line
of defence in reducing norovirus exposure and spread [67], and
is especially important in the immunocompromised population
[7]. Hospitals and long-term-care facilities caring for immuno-
compromised patients should adhere strictly to rigorous
infection control practices, to limit exposure of patients, staff
and visitors to noroviruses [68]. Immunocompromised individ-
uals should follow food safety guidelines that minimize exposure
to contaminated food and water, and avoid contact with
individuals who might be ill. The US CDC has published online
guidelines for the prevention of norovirus infection, including
management in healthcare settings www.cdc.gov/norovirus/
index.html and resources on effective disinfectants. Infection
control strategies with the most positive outcomes have been
reviewed in the nosocomial setting [66], and include restricting
movement of patients and staff, enhanced environmental
cleaning, and attention to hand-washing. The practice of
‘presenteesim’ (a term for working while sick) should be
avoided by healthcare workers managing immunocompromised
patients: this practice has been linked to norovirus outbreaks in
settings such as a bone marrow transplantation unit [26].
Vaccines
Norovirus vaccine development and evaluation is underway
[69], but it will probably be several more years before licensed
vaccines are available [70]. Immune correlates are not fully
understood, but it is presumed that the adaptive immune
system, including antibodies, CD4 lymphocytes, and CD8
lymphocytes, is critical in protection [46,71]. This is supported
by data from a norovirus vaccine study that showed a
correlation between the presence of serum antibodies with a
histo-blood group antigen blocking titre of at least 200 and a
reduced frequency of viral illness and infection upon virus
challenge [69]. A norovirus vaccine may be of limited use in the
general immunocompromised population with debilitated
T-cell and B-cell function, with the exception of patients
who would be eligible for incorporation of norovirus vaccina-
tion (when available) into the panel of recommended vaccines
administered prior to or following organ or stem cell
transplantation and IST [72]. Effective norovirus vaccines that
lower the overall disease prevalence in the general population
or in healthcare workers could indirectly beneﬁt immunode-
ﬁcient individuals by lowering the risk of exposure and
subsequent infection.
Antiviral drugs
Noroviruses associated with human disease do not grow in
cell culture, so drug design and screening have relied primarily
on recombinant DNA-based research tools (such as recombi-
nant norovirus replicative enzymes) or cell culture-adapted
calicivirus models, such as MNV or FCV. A number of
compounds, inhibitors and therapeutic antibodies are under
investigation in the basic research setting [8,73]. Promising
candidate drugs for the noroviruses will require safety and
efﬁcacy testing in adult volunteer challenge studies, and a
proposed design of clinical drug trials in immunocompromised
patients has recently been described [8].
Future Perspectives
Noroviruses are increasingly being recognized to constitute a
major risk factor for debilitating diarrhoea and chronic
gastroenteritis in immunocompromised patients. It is not
known whether these individuals play a major role in the
epidemiology of the virus, or are responsible for only sporadic
and occasional transmission. There is a need for effective
treatment in this special at-risk population to clear chronic
norovirus infection and restore normal intestinal function.
Such treatment may also offer beneﬁts to patient groups who
are at risk from acute life-threatening diarrhoea, including
infants, young children, and the elderly.
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